Jonathan Douxfils

Personal profile

Diplomas

Areas of expertise

Awards

External responsibilities

CEO of QUALIblood sa

Co-Chairman of the SSC Control of Anticoagulation of the Interntional Society on Thrombosis and Hemostasis

Pharmacovigilance Expert at the Federal Agency of Medicines and Health Products

Education/Academic qualification

Doctor of Pharmacy, University of Namur

Master of Pharmacy, Université Catholique de Louvain (UCL)

Bachelor of Pharmacy, University of Namur

External positions

Chief Executive Officer, Qualiblood

Nov 2017 → …

Co-Chairman, International Society on Thrombosis and Haemostasis

Nov 2016 → …

Fingerprint Dive into the research topics where Jonathan Douxfils is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

20 Similar Profiles

Anticoagulants Medicine & Life Sciences

Hemorrhage Medicine & Life Sciences

Thrombin Medicine & Life Sciences

Prothrombin Time Medicine & Life Sciences

Heparin Medicine & Life Sciences

Protein-Tyrosine Kinases Medicine & Life Sciences

Partial Thromboplastin Time Medicine & Life Sciences

Atrial Fibrillation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2019 2019

5 Not started

The HIC Project - evaluation of hormone-induced coagulopathy

Dogne, J., Douxfils, J. & Morimont, L.

1/09/19 → …

Project: PHD

The AVRI project - evaluation of the risk of radiotherapy-induced atherosclerosis

Douxfils, J.

Project: Research

The MAS project - Measure And See the activity of director oral anticoagulant in the clinical context

Douxfils, J. & Mullier, F.

Project: Research

The CAF project - a new tool for the assessment of the clot formation

Douxfils, J., Dogne, J. & Evrard, J.

Project: Research

The TiTKI Project - evaluation of the risk of thrombosis associated with the use of tyrosine kinase inhibitors

Douxfils, J., Mullier, F. & Haguet, H.

Project: PHD

Research Output 2010 2019

1517 Citations
20 h-Index
64 Poster
62 Conference contribution
40 Article
19 Review article
9 More

Andexanet alfa for the reversal of factor Xa inhibitors

Favresse, J., Hardy, M., van Dievoet, M. A., Sennesael, A. L., Douxfils, J., Samama, C. M., Vornicu, O., Dincq, A. S., Lessire, S. & Mullier, F., 2019, In : Expert Opinion on Biological Therapy. 19, 5, p. 387-397 11 p.

Research output: Contribution to journal › Review article

Pharmacodynamics

Hemorrhage

Phase III Clinical Trials

Factor Xa

Pharmacokinetics

An update on laboratory assessment for direct oral anticoagulants (DOACs)

Gosselin, R. C., Adcock, D. M. & Douxfils, J., 2019, In : International Journal of Laboratory Hematology. 41 Suppl 1, p. 33-39 7 p.

Research output: Contribution to journal › Review article

Anticoagulants

Pharmacodynamics

Pharmacokinetics

Antithrombins

Warfarin

Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application

Douxfils, J., Morimont, L., Bouvy, C., de Saint-Hubert, M., Devalet, B., Devroye, C., Dincq, A-S., Dogné, J-M., Guldenpfennig, M., Baudar, J., Larock, A-S., Lessire, S. & Mullier, F., 2019, In : Journal of thrombosis and haemostasis : JTH.

Research output: Contribution to journal › Article

Thrombin

Freezing

Reference Values

Low Molecular Weight Heparin

Anticoagulants

Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent

Exner, T., Favresse, J., Lessire, S., Douxfils, J. & Mullier, F., 2019, In : Thrombosis Research. 179, p. 69-72 4 p.

Research output: Contribution to journal › Article

Coagulants

Partial Thromboplastin Time

Prothrombin Time

Blood Coagulation Factors

Comparison of the impact of DOACs on hemostasis diagnostic tests

Siriez, R., Evrard, J., Dogne, J-M., Mullier, F. & Douxfils, J., 2019, Comparison of the impact of DOACs on hemostasis diagnostic tests.

Research output: Contribution in Book/Catalog/Report/Conference proceeding › Conference contribution

File

Datasets

Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis

Graux, C. (Contributor), Figshare, 29 Nov 2016

DOI: 10.6084/m9.figshare.4265168.v1, https://figshare.com/articles/Risk_of_arterial_and_venous_occlusive_events_in_chronic_myeloid_leukemia_patients_treated_with_new_generation_BCR-ABL_tyrosine_kinase_inhibitors_a_systematic_review_and_meta-analysis/4265168/1 and one more link, https://ndownloader.figshare.com/files/6948968 (show fewer)

Dataset